Roxane Laboratories Ohio Plant Undergoing $50 million Expansion

---

Researched by Industrialinfo.com (Industrial Information Resources, Incorporated; Houston, Texas). A major expansion project is now underway at the Roxane Laboratories' Columbus, Ohio plant. (PLANT 1513683) (PEC 10002761). Privately owned, Boehringer Ingelheim (BI) Corporation (Ingelheim, Germany), Roxane's parent company, had originally planned to spend $24.5 million on the project, which has now evolved into a $50 million investment.

BI is ramping up production capacity at the Roxane plant in anticipation of the upcoming regulatory approval by the US Food and Drug Administration (FDA) of their drug, Spiriva, a therapy used for the treatment of bronchitis, emphysema and other respiratory problems. Spiriva is already approved for use in Europe and the company does not expect to encounter any regulatory obstacles. Pfizer (NYSE:PFE) New York, New York will join BI in marketing the drug throughout the world.

Click the following link to view Industrialinfo.com's 2003 North American Pharmaceutical-Biotech Forecast